News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novogen Limited (NVGN) To Present At Biotech Showcase™ 2014


1/8/2014 7:06:35 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

SYDNEY, Jan. 8, 2014 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., its Executive Chairman and Chief Executive Officer, is scheduled to present a company overview to investors, pharmaceutical and healthcare executives attending the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, Calif.

(Logo: http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )

Slides to accompany the presentation will be available for download on Monday, January 13 on the Novogen website.

Details of the presentation are as follows:

Date: Tuesday, January 14, 2014
Time: 2:00 p.m. PST
Place: Parc 55 Wyndham San Francisco, Union Square
Track: C - Room Mission II

About Novogen Limited

Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's website, www.novogen.com.

SOURCE Novogen Limited



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES